The U.S Food & Drug Administration has granted approval for a targeted therapy called CABOMETYX ® to treat pancreatic ...

The Food and Drug Administration (FDA) recently approved a new targeted chemotherapy drug for adults with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer.

The EU approved AstraZeneca's Enhertu for certain breast cancer patients and Imfinzi for resectable NSCLC, showing ...

No improvement in overall survival (OS) was observed with palbociclib (Verzenio) plus endocrine therapy versus capecitabine in premenopausal patients with hormone receptor-positive, HER2-negative ...

Cabozantinib, an oral tyrosine kinase inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with previously treated advanced neuroendocrine tumors ...

—According to a new study, visceral involvement and the duration of treatment with endocrine therapy plus cyclin-dependent kinase 4/6 inhibitors were associated with survival in patients with ...

The FDA has given Roche its first regulatory approval for PI3K inhibitor Itovebi, clearing the drug as part of a triple therapy for certain types of locally advanced or metastatic breast cancer.

The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer treatment for patients who received endocrine therapy but are not suitable for ...